Advertisement
U.S. markets closed

Becton, Dickinson and Company (BDX)

NYSE - NYSE Delayed Price. Currency in USD
237.72+1.01 (+0.43%)
At close: 04:00PM EDT
237.72 0.00 (0.00%)
After hours: 06:00PM EDT

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800
https://www.bd.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full Time Employees73,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Thomas E. Polen Jr.President, CEO & Chairman3.46MN/A1973
Mr. Christopher J. DelOreficeExecutive VP & CFO1.6MN/A1972
Ms. Shana Carol NealExecutive VP & Chief People Officer1.79MN/A1966
Mr. David B. HickeyExecutive VP & President of Life Sciences Segment1.11M562.03k1964
Mr. Michael GarrisonExecutive VP & President of Medical segment1.73MN/A1970
Mr. Thomas J. SpoerelSenior VP, Controller & Chief Accounting OfficerN/AN/A1979
Ms. Elizabeth McCombsExecutive VP & Chief Technology OfficerN/AN/A1976
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D.Senior VP, Chief Scientific Officer & Co-Chair of Scientific Advisory BoardN/AN/AN/A
Ms. Denise Russell FlemingExecutive VP of Technology & Global Services and Chief Information OfficerN/AN/A1970
Mr. Greg RodetisHead of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of March 1, 2024 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.